Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A multicentre, open-label, randomized, controlled phase II trial evaluating the efficacy of dasatinib + irinotecan + rapamycin + temozolomide or irinotecan + temozolomide in patients aged 1-25 years with high-risk relapsed or refractory neuroblastoma
Primary Outcome Measures:
Progression-free survival (PFS)
The authors' conclusion was: RIST-rNB-2011 demonstrated that targeting MYCN-amplified relapsed or refractory neuroblastoma with a pathway-directed metronomic combination of a multikinase inhibitor and an mTOR inhibitor c…